S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
A.I. ETF Sold Out Of Monster Energy, Three Ways To Look At It
AI is Unstoppable. Now Is The Time! (Ad)
Stock market today: Wall Street futures point higher on debt deal, but some tremors in retail
The Most Upgraded Stocks From The Q1 Earnings Season
AI is Unstoppable. Now Is The Time! (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can These Two Crypto Stocks Stage a Comeback?
AI is Unstoppable. Now Is The Time! (Ad)
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
UiPath Stock Has Short-Term Pain for Long-Term AI Gain
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
A.I. ETF Sold Out Of Monster Energy, Three Ways To Look At It
AI is Unstoppable. Now Is The Time! (Ad)
Stock market today: Wall Street futures point higher on debt deal, but some tremors in retail
The Most Upgraded Stocks From The Q1 Earnings Season
AI is Unstoppable. Now Is The Time! (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can These Two Crypto Stocks Stage a Comeback?
AI is Unstoppable. Now Is The Time! (Ad)
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
UiPath Stock Has Short-Term Pain for Long-Term AI Gain
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
A.I. ETF Sold Out Of Monster Energy, Three Ways To Look At It
AI is Unstoppable. Now Is The Time! (Ad)
Stock market today: Wall Street futures point higher on debt deal, but some tremors in retail
The Most Upgraded Stocks From The Q1 Earnings Season
AI is Unstoppable. Now Is The Time! (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can These Two Crypto Stocks Stage a Comeback?
AI is Unstoppable. Now Is The Time! (Ad)
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
UiPath Stock Has Short-Term Pain for Long-Term AI Gain
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
A.I. ETF Sold Out Of Monster Energy, Three Ways To Look At It
AI is Unstoppable. Now Is The Time! (Ad)
Stock market today: Wall Street futures point higher on debt deal, but some tremors in retail
The Most Upgraded Stocks From The Q1 Earnings Season
AI is Unstoppable. Now Is The Time! (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can These Two Crypto Stocks Stage a Comeback?
AI is Unstoppable. Now Is The Time! (Ad)
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
UiPath Stock Has Short-Term Pain for Long-Term AI Gain
NYSE:ENZ

Enzo Biochem (ENZ) Stock Forecast, Price & News

$2.20
-0.08 (-3.51%)
(As of 05/31/2023 ET)
Compare
Today's Range
$2.18
$2.24
50-Day Range
$2.13
$2.66
52-Week Range
$1.00
$2.75
Volume
143,931 shs
Average Volume
127,460 shs
Market Capitalization
$109.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ENZ stock logo

About Enzo Biochem (NYSE:ENZ) Stock

Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. It operates through the following segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Therapeutics segment conducts research and development activities for therapeutic drug candidates. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Stock News Headlines

AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
Enzo Biochem (NYSE:ENZ) Now Covered by StockNews.com
StockNews.com Begins Coverage on Enzo Biochem (NYSE:ENZ)
Comparing Akumin (NASDAQ:AKU) & Enzo Biochem (NYSE:ENZ)
8-K: ENZO BIOCHEM INC
See More Headlines
Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Company Calendar

Last Earnings
3/20/2023
Today
5/31/2023
Next Earnings (Estimated)
6/08/2023
Fiscal Year End
7/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Employees
451
Year Founded
1976

Profitability

Net Income
$-18,260,000.00
Pretax Margin
-43.44%

Debt

Sales & Book Value

Annual Sales
$107.07 million
Book Value
$1.12 per share

Miscellaneous

Free Float
41,965,000
Market Cap
$109.25 million
Optionable
Optionable
Beta
1.04

Social Links


Key Executives

  • Hamid Erfanian
    Chief Executive Officer & Director
  • Kara Cannon
    Chief Operating Officer
  • Patricia Eckert
    Chief Financial Officer
  • Dieter Schapfel
    Chief Medical Director
  • Matthew Kupferberg
    Secretary & General Counsel













ENZ Stock - Frequently Asked Questions

How have ENZ shares performed in 2023?

Enzo Biochem's stock was trading at $1.43 at the beginning of the year. Since then, ENZ shares have increased by 53.8% and is now trading at $2.20.
View the best growth stocks for 2023 here
.

Are investors shorting Enzo Biochem?

Enzo Biochem saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 1,220,000 shares, an increase of 8.9% from the April 15th total of 1,120,000 shares. Based on an average trading volume of 849,700 shares, the short-interest ratio is currently 1.4 days. Approximately 3.7% of the shares of the company are sold short.
View Enzo Biochem's Short Interest
.

When is Enzo Biochem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 8th 2023.
View our ENZ earnings forecast
.

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) issued its quarterly earnings data on Monday, March, 20th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter. The medical research company had revenue of $16.34 million for the quarter. Enzo Biochem had a negative net margin of 43.44% and a negative trailing twelve-month return on equity of 67.73%.

What other stocks do shareholders of Enzo Biochem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU).

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

Who are Enzo Biochem's major shareholders?

Enzo Biochem's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (5.58%), Dimensional Fund Advisors LP (3.06%), BlackRock Inc. (2.86%), Roumell Asset Management LLC (1.82%), Potomac Capital Management Inc. (1.57%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Bradley Louis Radoff, David Bench, Discovery Fund Lp Harbert, Hamid Erfanian, James G Wolf and Kara Cannon.
View institutional ownership trends
.

How do I buy shares of Enzo Biochem?

Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $2.20.

How much money does Enzo Biochem make?

Enzo Biochem (NYSE:ENZ) has a market capitalization of $109.25 million and generates $107.07 million in revenue each year. The medical research company earns $-18,260,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis.

How many employees does Enzo Biochem have?

The company employs 451 workers across the globe.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The official website for the company is www.enzo.com. The medical research company can be reached via phone at (212) 583-0100, via email at ir@enzo.com, or via fax at 212-679-7999.

This page (NYSE:ENZ) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -